Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25982018 | 0.83 | HSP90AA1 (0.38) | HTTHSP90AA1HSP90AB1TDP1 | |
| SCHEMBL25411344 | 0.83 | HTT (0.33) | HTTHSP90AA1HSP90AB1 | |
| SCHEMBL22028950 | 0.80 | HSP90AA1 (0.36) | HTTHSP90AA1HSP90AB1 | |
| SCHEMBL29851065 | 0.80 | HSP90AA1 (0.36) | HTTHSP90AA1HSP90AB1 | |
| SCHEMBL24254975 | 0.71 | ADORA3 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL11985866 | 0.70 | TDP1 (0.35) | TDP1 | |
| SCHEMBL13550096 | 0.70 | PTGS2 (0.33) | HTT | |
| SCHEMBL24272757 | 0.68 | — | — | |
| SCHEMBL21261372 | 0.67 | TDP1 (0.40) | TDP1 | |
| SCHEMBL29344230 | 0.67 | CA1 (0.40) | HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074893-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250059155-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| CN-119192133-A | Synthesis of quinazoline compounds | 基因泰克公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119192134-A | Synthesis of quinazoline compounds | 基因泰克公司 | 2024-12-27 | — | — | CN | disclosed |
| US-12172982-B2 | Synthesis of quinazoline compounds | GENENTECH, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4476205-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | Genentech Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-116057052-B | Synthesis of quinazoline compounds | 基因泰克公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118574820-A | Method for synthesizing quinazoline compounds | 基因泰克公司 | 2024-08-30 | — | — | CN | disclosed |
| US-12071422-B2 | Process for synthesis of quinazoline compounds | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2023150653-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150653-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| EP-4196470-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | Genentech, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| CN-116057052-A | Synthesis of quinazoline compounds | 基因泰克公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| WO-2022035790-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022035790-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | COQ8A, SQSTM1, QARS1 | HTT 982/4885HSP90AA1 4305/4885HSP90AB1 4357/4885 |
| US-12071422-B2 | Process for synthesis of quinazoline compounds | HCCS, NQO2, SQLE | HTT 4101/4885HSP90AA1 3541/4885HSP90AB1 3192/4885 |
| US-12172982-B2 | Synthesis of quinazoline compounds | COQ8A, SQSTM1, QARS1 | HTT 982/4885HSP90AA1 4305/4885HSP90AB1 4357/4885 |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | HTT 4101/4885HSP90AA1 3541/4885HSP90AB1 3192/4885 |
| US-20250059155-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | HTT 4101/4885HSP90AA1 3541/4885HSP90AB1 3192/4885 |
| US-20250074893-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | COQ8A, SQSTM1, QARS1 | HTT 982/4885HSP90AA1 4305/4885HSP90AB1 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.